Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

Abstract

Existing guidelines on respiratory syncytial virus (RSV) prophylaxis differ greatly by gestational age (GA) and other underlying risk factors, highlighting the data gaps in RSV disease burden among preterm infants. We will conduct a systematic review and individual participant data (IPD) meta-analysis of RSV global disease burden among preterm-born children. Three databases, Medline, Embase, and Global Health, will be searched for relevant studies on RSV disease burden for 2019 or before in preterm-born children published between 1 January 1995 and 31 December 2021. IPD will be sought by contacting the investigators identified from published literature and from existing collaboration networks. One-stage and 2-stage random-effects meta-analyses will be used to combine information from IPD and non-IPD studies to produce summary RSV burden estimates of incidence rate, hospital admission rate, and in-hospital case fatality ratio. The framework will be extended to examine subgroup(s) with the most substantial RSV disease burden.

Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Unsuccessful Vaccine Candidates.

“…Preterm infants, particularly those born prematurely, are disproportionally affected by RSV-related illness, experiencing notably higher rates of hospitalization. These findings emphasize the need of potential immunization early during pregnancy [47]. The FDA mandated a specialized report on preterm births and hypertension during pregnancy using real-world data through the Vaccine Adverse Event Reporting System (VAERS) and established precise pharmacovigilance objectives for ABRYSVO.…”

Incidence and Transmission of SARS-CoV-2 in US Child Care Centers After COVID-19 Vaccines

“…With widespread SARS-CoV-2 immunity from vaccines and prior infections and the expiration of the public health emergency, it is appropriate to reassess recommended exclusion criteria, which still include testing anyone with respiratory symptoms and staying home if positive for at least 5 days. 26 Children with respiratory syncytial virus infection and influenza, both known to spread quickly within CCCs and to households 27 , 28 , 29 , 30 and with similar morbidity to SARS-CoV-2, 2 , 3 , 31 , 32 , 33 , 34 may return to CCCs once they are behaviorally able to participate without requiring excess care and after fever has resolved for 24 hours without antipyretics, 35 , 36 which is often less than 5 days. Our findings support relaxing SARS-CoV-2 testing and exclusion recommendations for mildly symptomatic or exposed children.…”